Modern CINV prevention: fewer medications, greater comfort for the patient and the therapeutic team Artykuł przeglądowy

##plugins.themes.bootstrap3.article.sidebar##

PDF (English)


Opublikowane: wrz 30, 2025
DOI: https://doi.org/10.24292/01.OR.152991025
Słowa kluczowe:
CINV, antiemetic treatment, nausea and vomiting

##plugins.themes.bootstrap3.article.main##

Łukasz Hajac
Department of Clinical Oncology/Chemotherapy, Lower Silesian Center for Oncology, Pulmonology, and Hematology in Wrocław
Martyna Hajac
Department of Environmental Health, Occupational Medicine, and Epidemiology, Medical University of Wrocław
Piotr Hudziec
Department of Clinical Oncology/Chemotherapy, Lower Silesian Center for Oncology, Pulmonology, and Hematology in Wrocław

Abstrakt

Nausea and vomiting are among the most frequently reported adverse effects of systemic oncological treatment. Effective prevention is key to improving patients’ quality of life. Nausea and vomiting can be early, late, or preemptive. Both the mechanism of their onset and the therapeutic methods vary. Treatment primarily involves 5-HT3 antagonists, glucocorticosteroids, NK1 antagonists, and olanzapine. Modern antiemetic therapy is safe and effective in most cases. The most common side effects include headache, constipation, and sedation.

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

##plugins.themes.bootstrap3.article.details##

Jak cytować
1.
Hajac Łukasz, Hajac M, Hudziec P. Modern CINV prevention: fewer medications, greater comfort for the patient and the therapeutic team. OncoReview [Internet]. 30 wrzesień 2025 [cytowane 10 czerwiec 2026];15(2(58):41-5. Dostępne na: https://www.journalsmededu.pl/index.php/OncoReview/article/view/3453
Numer
Tom 15 Nr 2(58) (2025)
Dział
PERSONALIZED ONCOLOGY

Copyright: ? Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

Bibliografia

1. Leppert W, Woroń J. Nudności i wymioty u chorych na nowotwory – zalecenia postępowania terapeutycznego. Med Paliatywna w Prakt. 2016; 10(3): 98-111.
2. Shankar A, Roy S, Malik A et al. Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients. Asian Pac J Cancer Prev. 2015; 16(15): 6207-13. http://doi.org/10.7314/apjcp.2015.16.15.6207.
3. Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016; 374(14): 1356-67. http://doi.org/10.1056/NEJMra1515442.
4. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherap-induced emesis: results of Perugia Consensus Conference. Ann Oncol. 1998; 9(Aug): 811-9. http://doi.org/10.1093/annonc/mdj078.
5. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol Off J Eur Soc Med Oncol. 2010; 21(Suppl. 5): v232-43. http://doi.org/10.1093/annonc/mdq194.
6. Herrstedt J, Clark-Snow R, Ruhlmann CH et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024; 9(2): 102195. http://doi.org/10.1016/j.esmoop.2023.102195.
7. Kawecki A, Krzakowski M. Chemotherapy- and radiotherapy-induced nausea and vomiting. Oncol Clin Pract. 2018; 14(2): 53-61. http://doi.org/10.5603/OCP.2018.0010.
8. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2011; 29(31): 4189-98. http://doi.org/10.1200/JCO.2010.34.4614.
9. Freites-Martinez A, Santana N, Arias-Santiago S et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr. 2021; 112(1): 90-2. http://doi.org/10.1016/j.ad.2019.05.009.
10. Grunberg SM, Warr D, Gralla RJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – state of the art. Support Care Cancer. 2011; 19(1): 43-7. http://doi.org/10.1007/s00520-010-1003-x.
11. Dupuis LL, Robinson PD, Boodhan S et al. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer. 2014; 61(8): 1506-12. http://doi.org/10.1002/pbc.25063.
12. Navari RM. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol. 2009; 5(12): 1577-86. http://doi.org/10.1517/17425250903407289.
13. Hesketh PJ, Rossi G, Rizzi G et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol Off J Eur Soc Med Oncol. 2014; 25(7): 1340-16. http://doi.org/10.1093/annonc/mdu110.